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MultiCode-PLx System for Multiplexed Detection of
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The MultiCode-PLx system (EraGen Biosciences, Inc., Madison, WI) for the detection of respiratory viruses
uses an expanded genetic alphabet, multiplex PCR chemistry, and microsphere flow cytometry to rapidly detect
and specifically identify 17 different respiratory viruses directly in clinical specimens. The MultiCode-PLx
system was tested in parallel with direct fluorescent-antibody (DFA) staining and rapid shell vial culture
(R-mix cells; Diagnostic Hybrids, Inc. Athens, OH) with 354 respiratory specimens from adult patients that
were submitted to the clinical virology laboratory at the Emory University Hospital. Single-target PCRs were
performed with retained samples to confirm the positive results obtained with the MultiCode-PLx system for
viruses not covered by DFA and R-mix culture (metapneumovirus, coronaviruses [CoV], parainfluenza viruses
4a and 4b, and rhinoviruses) and to resolve any discrepancies between the DFA and R-mix culture and the
MultiCode-PLx results for viruses common to both systems. Respiratory viruses were detected in 77 (21.8%)
and 116 (32.7%) specimens by DFA and R-mix culture and with the MultiCode-PLx system, respectively.
Among the viruses common to both systems, the MultiCode-PLx system detected significantly more influenza
A viruses (P  0.0026). An additional increased diagnostic yield with the MultiCode-PLx system resulted from
the detection of human metapneumovirus (HMPV) in 9 specimens, human CoV (HCoV) in 3 specimens, and
human rhinovirus (HRV) in 16 specimens. Also, two mixed viral infections were detected by the MultiCode-PLx
system (HCoV OC43 and HRV infections and HMPV and HRV infections), but none were detected by DFA and
R-mix culture. Single-target PCRs verified the results obtained with the MultiCode-PLx system for 73 of 81
(90.1%) specimens that had discordant results or that were not covered by DFA and R-mix culture. The
MultiCode-PLx system provides clinical laboratories with a practical, rapid, and sensitive means for the
massively multiplexed molecular detection of common respiratory viruses.
Respiratory viral infections are the most common reason for
medical consultation and are associated with a wide range of
clinical manifestations, ranging from self-limited upper respi-
ratory tract infections to more serious lower respiratory tract
infections. Concerns about pandemic influenza, emerging
threats to humans posed by zoonotic infections with avian
influenza viruses and the sudden acute respiratory syndrome
coronavirus (CoV), and the discovery of several previously
unrecognized viral pathogens have placed a premium on res-
piratory virus surveillance and diagnosis (18, 19).
Currently, there are approximately 200 known respiratory
viruses belonging to the families Adenoviridae, Parvoviridae,
Orthomyxoviridae,Paramyxoviridae,Picornaviridae, andCorona-
viridae (1). The virology of respiratory tract infections contin-
ues to evolve rapidly, with both the discovery of new pathogens
and a better understanding of the importance of infections
caused by the well-established ones. In the past several years
human metapneumovirus (HMPV) (30), several new human
CoVs (HCoVs) (10, 13, 17, 31, 34), and human bocavirus (2)
have been added to the ever expanding list of respiratory viral
pathogens. Despite these advances, a specific etiologic agent
for viral respiratory illness is often not identified in clinical
practice because of a lack of tests sensitive for the detection of
all known agents and the presence of yet unrecognized patho-
gens.
Historically, standard viral detection techniques have relied
on isolation of the virus in cell culture and immunoassays for
viral antigens performed directly with clinical specimens. More
recently, nucleic acid amplifications methods have been used
to detect respiratory viruses, often with dramatic increases in
sensitivity (14). However, the diversity and the complexity of
the viral flora present significant challenges for nucleic acid-
based detection systems. Multiplex PCR and microarrray-
based systems for the detection of respiratory viruses provide
potential solutions to this complex diagnostic problem. How-
ever, the numbers of viruses detectable in a single assay are
relatively small in published reports of multiplexed PCRs for
the detection of respiratory viruses (4, 5, 8, 12, 14, 16), and
microarrays (32) are not practical for use in clinical laborato-
ries.
The MultiCode-PLx system (EraGen Biosciences, Inc.,
Madison, WI) is a new multitarget, high-throughput technol-
ogy that integrates multiplexed PCR, an expanded genetic
alphabet, and microsphere flow cytometry. Use of the Multi-
* Corresponding author. Present address: Medical University of
South Carolina, Pathology and Laboratory Medicine, 165 Ashley Ave.,
Suite 309, P.O. Box 250908, Charleston, SC 29425. Phone: (843) 792-
5020. Fax: (843) 792-7060. E-mail: nolte@musc.edu.
 Published ahead of print on 27 June 2007.
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Code-PLx system involves three major steps: PCR, target spe-
cific extension, and liquid chip decoding (Fig. 1). An initial
reverse transcription (RT) step is added for RNA targets. It
uses an additional nucleobase base pair not found in nature
that is constructed from the complementary bases isoguanine
(iG) and 5-methyl-isocytidine (iC) for site-specific enzymatic
labeling and wash-free decoding at room temperature. All
steps are carried out in the same reaction vessel, without trans-
fers or washings, and are completed in about 4 h. The Multi-
Code-PLx system can simultaneously detect up to 80 targets in
one reaction and has successfully been applied to screening for
multiple mutations in patients with cystic fibrosis (20), single-
nucleotide polymorphism analysis of PECAM-1 (28), and hu-
man minor histocompatibility antigen genotyping (27).
In this study, an alpha prototype version of the MultiCode-
PLx system for the detection of 17 different respiratory viruses
was evaluated for its feasibility and diagnostic yield in the
clinical laboratory setting. The results obtained with the Multi-
Code-PLx system were compared with the results obtained by
direct fluorescent-antibody (DFA) staining and rapid shell vial
culture (R-mix cells; Diagnostic Hybrids, Inc. Athens, OH) for
respiratory specimens that were submitted to the clinical virol-
ogy laboratory of the Emory University Hospital for culture.
Single-target PCRs were performed with retained samples to
confirm positive MultiCode-PLx system results for viruses not
covered by DFA and R-mix culture (HMPV, HCoV, para-
influenza viruses [PIVs] 4a and 4b, and human rhinovirus
[HRV]) and to resolve any discrepancies between the results
obtained by DFA and rapid culture and those obtained by use
of the MultiCode-PLx system for viruses common to both
systems.
MATERIALS AND METHODS
Samples. All respiratory tract specimens of sufficient volume from adult pa-
tients that were submitted to the clinical virology laboratory at the Emory
University Hospital for DFA staining and rapid culture between 7 November
2005 and 17 March 2006 were eligible for the study. Nasopharyngeal, nose,
throat, and lung tissue samples were collected and transported in viral transport
media. Bronchoscopy samples and sputa were collected and transported in sterile
containers without viral transport medium. All samples were transported to the
laboratory on ice. One milliliter of residual unprocessed samples was stored at
80°C for later testing with the MultiCode-PLx respiratory virus system.
DFA staining and rapid culture. Respiratory tract samples (2 to 4 ml each)
were centrifuged at low speed at room temperature for 10 min after addition of
0.3 ml of an antibiotic solution (Bartels Cultrol; Trinty Biotech, Jamestown, NY).
The cell pellet was used to prepare cytospin slides for DFA staining (Chemicon,
Temecula, CA) for respiratory syncytial virus (RSV), according to the manufac-
turer’s instructions. Three R-mix culture shell vials containing a mixed mono-
layer of human adenocarcinoma cells (A549 cells) and mink lung cells (Mv1Lu
cells) were inoculated with 0.2 ml each of the sample supernatant. The shell vials
were centrifuged at 700  g for 1 h at room temperature. The inoculated vials
were incubated at 35°C for up to 48 h. The coverslip was removed from one vial
after 16 to 24 h of incubation, washed, fixed in acetone, and stained with a
fluorescent monoclonal antibody pool containing antibodies to adenoviruses
(ADVs); influenza A virus (INF A); influenza B virus (INF B); PIVs 1, 2, and 3;
and RSV (Chemicon). The process was repeated with the coverslip from a
second vial at 42 to 48 h for those samples negative at 16 to 24 h. A cell
suspension was prepared from a remaining shell vial for samples that were
positive with the antibody pool, and a drop was added to each well of an
eight-well slide. Individual wells were then stained with a virus-specific mono-
clonal antibody reagent and examined under a fluorescent microscope to identify
which virus was present.
PLx RVP. One milliliter of residual unprocessed sample was centrifuged at 17,
000  g for 20 min at room temperature, and the cell pellet was resuspended in
approximately 200 l of supernatant. The nucleic acid extraction was performed
with a MagNA Pure LC instrument and by using a total nucleic acid kit (Roche
Diagnostics, Indianapolis, IN). The sample and elution volumes were 200 and 50
l, respectively. Each assay with the MultiCode-PLx system respiratory virus
panel (PLx RVP) was performed in a single well of a low-profile 96-well PCR
plate, as described by the manufacturer (EraGen). In brief, cDNA from viral
RNA was prepared by adding and mixing 10 l of extracted nucleic acid to 10 l
of reverse transcriptase solution. The reaction mixtures were sealed with an
adhesive film (Microseal A; Bio-Rad, Hercules, CA); incubated at 25°C for 5
min, 42°C for 10 min, 55°C for 20 min, and 85°C for 5 min; and then cooled to
4°C. The target DNAs were then amplified by PCR on a PTC-200 apparatus
(Bio-Rad) with the target-specific primer sets contained in the PCR master
mixture. For each viral target primer set, one target-specific primer contained a
single iC base at the 5 end for subsequent site-specific labeling with iso-GTP-
biotin. The amplification was performed by adding 5 l of the PCR master
mixture to 5 l of the target DNA preparation. The reaction mixtures were
sealed as described above and cycled 30 times by using the parameters of 95°C
for 10 s, 55°C for 30 s, and 72°C for 30 s. The amplified DNA was then used as
the template for the labeling of target-specific extenders. The labeling step,
termed target-specific extension (TSE), was performed by adding 5 l of TSE
solution to the amplification reaction, sealing the plates, and incubating the
plates at 65°C for 2 min and then 95°C for 10 s, with the incubation repeated 10
times. This was followed by a 5-min hold at 65°C, and then the plates were held
FIG. 1. Schematic of the major steps in the MultiCode-PLx respiratory virus detection system. For amplification, after RT, the target regions
are amplified by PCR with one of the primers containing a single iC base at the 5 end for subsequent site-specific labeling. For TSE, tagged,
target-specific extenders are site specifically labeled with biotin-di-iso-GTP when the correct amplicon is present by primer extension. For capture,
the tagged TSE products are captured by color-addressable microspheres through hybridization of each tag to its complementary, virus-specific
oligonucleotide code conjugated to the microsphere surface. Both the tags and codes also contain the iC and iG bases. After the addition of
streptavidin-phycoerythrin, the fluorescent signal associated with each microsphere is analyzed and decoded by using a Luminex 100 instrument.
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at 4°C. When the reactions were complete, the reaction mixtures were brought to
room temperature, 35 l of a capture master mixture was added, and the
components were mixed and allowed to sit for 10 min. The capture master
mixture includes the Fast-Shot 30 bead array. This array contains codes co-
valently coupled to color-coded microspheres that can be detected with a Lumi-
nex LabMap flow detector. The codes are short sequences containing iC and iG
and are complementary to specific tags on the extenders used in the previous step
(20). Next, 35 l of the detection master mixture was added to each reaction
mixture, and after 15 min, the entire plate of reactions was placed in the XY
platform of the Luminex 100 instrument. The fluorescent signal associated with
each microsphere was measured. The signal is expressed as the median fluores-
cence intensity (MFI). Samples with an average signal 6 standard deviations
above the average negative control signals were regarded as positive.
Two internal positive controls (IPCs) were used for each reaction performed:
an RNA extraction control and a DNA PCR control. For the extraction control,
30,000 copies of an inactivated mouse hepatitis virus (ZeptoMetrix, Buffalo,
NY) were added to 200 l of each sample prior to extraction. For the PCR
control, a DNA target and a set of primers and detectable extenders were present
in the PCR master mixture and TSE solution, respectively. A reportable signal in
the extraction control channel indicates that the control RNA added to the
sample was successfully extracted, reverse transcribed, and amplified and that
subsequent steps were performed correctly for that sample. Each IPC was
present at approximately 1,200 copies/reaction mixture. A reportable signal in
the PCR control channel indicates that the control DNA was successfully am-
plified and that the subsequent steps were correctly performed for that sample.
Ideally, both controls should report signals over the background signal. Report-
able signals for the extraction- and amplification-positive controls were defined
as MFI values of greater than 5,000 and 2,000, respectively. For samples for
which either IPC was not detected above the threshold, a no call was reported.
Single-target, real-time RT-PCR assays for HRV and HMPV and for HCoV.
Single-target, real-time RT-PCR assays for HRV and HMPV and for HCoV
were carried out in 50-l reaction volumes in optical-quality 96-well plates. Each
reaction mixture contained 1 QIAGEN (Valencia, CA) Quantitect Probe RT-
PCR kit reaction mixture. Thermal cycling was performed on an ABI 7300
real-time PCR instrument by using “absolute quantitation” software. The con-
ditions were as follows: for HCoV, 50°C for 20 min for 1 cycle, 95°C for 15 min
for 1 cycle, and 94°C for 15 s plus 60°C for 60 s for 45 cycles; for HRV and
HMPV, 50°C for 30 min, 95°C for 15 min, and then 45 cycles of 95°C for 15 s and
55°C for 1 min. Threshold crossing cycles were computed by use of ABI 7300
Real-Time PCR system sequence detection software (version 1.2.1). RT-PCR for
HRV was performed by the using primers and the minor groove binder (MGB)
modifications of the probes originally described by Deffernez et al. (9). The
primers and an MGB modification of the probe originally published by
Maertzdorf et al. (25) were used for HMPV. Except for the HRV-specific probes,
which were labeled with VIC at their 5 ends, the probes were labeled with
6-carboxyfluorescein (FAM) at their 5 ends and had the MGB peptide at their
3 ends. For the HCoV assays, primers and probes that amplify segments of the
N gene of human HCoVs OC43, 229E, and NL63/New Haven were used. The
primer and probes sequences used for the OC43 assay were as follows: forward
primer, GTTGTACAGGATGTGGGA; reverse primer, CGAACTTAGTCGT
CATGT; and probe, FAM-CTGGATACCAGGAGTT-MGB. The primer and
probe sequences used in the 229E assay were as follows: forward primer, TGC
ATTTTTATTATCTTGGC; reverse primer, TGAATTCTTGCGCCTAAC; and
probe, FAM-CTGTTGATGGTGCTAAA-MGB. The primer and probe se-
quences used in the NL63 assays were those described by Fouchier et al. (17).
HCoV strains were obtained from ATCC (strains OC43 and 229E) or from Lia
van der Hoek (strain NL63). For each HCoV we created and quantified in vitro
RNA transcripts from cloned segments that contained the assay target for each
strain.
Single-target PCR assays for INF A and RSVs A and B. The MultiCode-RTx
real-time PCR technology was used to design primers that target the fusion gene
of RSV and the matrix genes of INF A and INF B (29). The RSV assay consisted
of RSV A- and RSV B-specific forward primers and a common reverse primer,
which were used at 200 nM each. The INF A and INF B assays consisted of two
primer pairs, with one pair targeting the INF A matrix gene and the other
targeting the INF B matrix gene. The concentrations of the primer pairs were 150
and 200 nM in the INF A and INF B assays, respectively. The PCR conditions
involved 25-l reaction mixtures in 1 ISOlution buffer (EraGen) and Titanium
Taq DNA polymerase (Clontech, Palo Alto, CA) at the manufacturer’s recom-
mended concentration. For one-step MultiCode-RTx reverse transcriptase PCR
assays, the conditions included the following: 0.5 U/l Moloney murine leukemia
virus reverse transcriptase (Promega, Madison, WI) and 5 mM dithiothreitol,
with an additional 5 min at 50°C added prior to the initial denaturation step.
Alternatively, 5 l of the cDNA prepared as described above was used as the
template for the MultiCode-RTx assay. Real-time PCR was performed on an
ABI Prism 7900 real-time thermal cycler with 96-well optical plates. The PCR
cycling parameters were 2 min of denaturation at 95°C and 5 cycles of 5 s at 95°C,
10 s at 58°C, and 20 s at 72°C, followed by 45 cycles of 5 s at 95°C, 10 s at 63°C,
and 20 s at 72°C, with optical reading. A thermal melt at a 5% ramp rate with
optical reading from 60 to 95°C was performed directly following the last step of
thermal cycling at 72°C.
Alpha trial protocol. All samples included in the study were tested for respi-
ratory viruses by DFA staining with R-mix culture and by use of the MultiCode-
PLx system. Single-target PCRs were performed with retained samples to con-
firm the positive MultiCode-PLx system results for viruses not covered by DFA
staining and R-mix culture (HMPV, HCoV, PIVs 4a and 4b, and HRV) and to
resolve any discrepancies between the results of DFA and rapid culture and
those of the MultiCode-PLx system for viruses common to both systems (INF A;
INF B; PIVs 1, 2, and 3; ADV; and RSV).
RESULTS
A total of 421 tests were performed with the MultiCode-PLx
system and 377 specimens by two different operators in three
separate runs with a single lot of reagents during the course of
the study. The specimens types were as follows: 149, bronchos-
copy fluids; 134, nose swab; 73, nasopharyngeal swab; 8, throat
swab; 6, lung tissue; 1, sputum; and 6, unknown.
An example of the data output from a MultiCode-PLx sys-
tem run is shown in Fig. 2. The dot plots show results for the
INF A test (Fig. 2A) and the corresponding DNA (Fig. 2B)
and RNA (Fig. 2C) IPC results for 187 patient specimens and
5 no-template negative controls. In the run for which the re-
sults are shown in Fig. 2, 47 specimens had MFI values above
the threshold of 663 for the INF A test. MFI values for the
DNA IPC exceeded the threshold of 2,000 for all of the sam-
ples; however, the RNA IPC was not detected in three of the
patient specimens. The RNA IPC was not added to the no-
template negative controls.
The mean MFI values for all of the positive calls by the
MultiCode-PLx system and all of the negative calls for those
viruses included in the MultiCode-PLx system panel along with
the threshold values for the different tests are shown in Table
1. The background fluorescence was low for all tests, and the
mean MFI values for all specimens called positive by the Multi-
Code-PLx system were well above the positive thresholds for
each test (Table 1).
The DNA PCR control failed in 2.5% of the tests, and the
RNA extraction control failed in 8.7% of the tests. Twenty-
three patient specimens tested negative for viral targets in
which either IPC was not detected. Data for these samples
were excluded from the diagnostic yield calculations. For those
tests in which the IPCs were detected, the MFI values were
highly reproducible, with coefficients of variation for the PCR
and extraction controls of 13 and 14%, respectively. None of
the negative controls included in each MultiCode-PLx system
run tested positive for any of the 19 different targets.
The respiratory viruses detected by each test system for the
354 specimens included in the analysis are given in Table 2.
Overall, 77 viruses were detected by DFA and R-mix culture in
77 specimens, and 118 viruses were detected with the Multi-
Code-PLx system in 116 specimens. The overall diagnostic
yields for DFA plus R-mix culture and MultiCode-PLx system
were 21.8% and 32.7%, respectively. For the viruses common
to both test systems, the yields were similar for INF B’s, RSVs,
ADVs, and PIVs. However, significantly more INF A’s were
VOL. 45, 2007 MultiCode-PLx SYSTEM FOR RESPIRATORY VIRUS DETECTION 2781
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detected with the MultiCode-PLx system than by rapid culture
(P  0.0026, McNemar’s test).
A two-by-two contingency table for the detection of INF A
by the different test methods was prepared, and the results
were as follows: among the samples with positive MultiCode-
PLx system results, 55 were R-mix culture positive and 19 were
R-mix culture negative (of these, 17 [89.5%] tested positive for
INF A by a single-target PCR assay). Among the samples with
negative MultiCode-PLx system results, 4 were R-mix culture
positive (of these, 3 [75%] samples tested positive for INF A by
a single-target PCR assay) and 276 were R-mix culture nega-
tive. The agreement between the MultiCode-PLx system and
R-mix culture for the detection of INF A was 93.5%. The
FIG. 2. Sample data output from the MultiCode-PLx respiratory virus detection system. The dot plots show the MFIs for 187 patient specimens
and 5 negative controls for the INF A target (A) and the corresponding DNA (B) and RNA (C) IPCs. Forty-seven samples had MFI values above
the threshold for the INF A test. MFI values for the DNA IPC exceeded the threshold for all samples. The RNA IPC was not detected in three
(1.6%) of the patient specimens.
TABLE 1. Mean MFI values for positive and negative calls with
clinical specimens in the MultiCode-PLx respiratory virus system
Virus ThresholdMFI Call
No. of
tests
Mean
MFI SD
HRV 962 Negative 401 154 79.3
Positive 20 7,890 1,500
INF A 906 Negative 329 161 79.6
Positive 92 5,850 2,250
INF B 1,026 Negative 419 177 85.1
Positive 2 5,280 1,780
PIV 1 943 Negative 419 161 88.3
Positive 2 4,010 279
RSV A 898 Negative 410 153 81.3
Positive 11 7,000 2,540
RSV B 963 Negative 418 143 77.1
Positive 3 2,380 1,080
HMPV 1,015 Negative 412 155 79.6
Positive 9 6,770 2,380
ADV C 1,037 Negative 420 153 86.4
Positive 1 2,200
OC43 946 Negative 420 159 86.4
Positive 1 1,860
NL63 900 Negative 419 156 82.3
Positive 2 1,810 1,070
TABLE 2. Diagnostic yield from DFA staining plus R-mix culture
and the MultiCode-PLx system for detection of respiratory
viruses in 354 respiratory specimens
Virus and summary result
No. of specimens detected by:
DFA and R-mix
culture
MultiCode-PLx
system
INF A 59 74
INF B 1 1
RSV 12 13 (A, 10;
B, 3)
ADV 1 1 (C)
PIV 1 3 2
Pool positive onlya 1
HMPV 9
HRV 16
NL63 2
OC43 1
No. of viruses detected 77 118.3
No. of positive specimens 77 116b
Diagnostic yield (%) 21.8 32.7
a Unable to specifically identify the virus present with individual virus-specific
monoclonal antibodies. The sample was positive for INF A with the MultiCode-
PLx system.
b Two mixed infections were detected: OC43 and HRV infections and HMPV
and HRV infections.
2782 NOLTE ET AL. J. CLIN. MICROBIOL.
 o
n
 M
arch 22, 2014 by W
ashington University in St. Louis
http://jcm.asm.org/
D
ow
nloaded from
 
sensitivity and specificity of the MultiCode-PLx system relative
to the results of R-mix culture were 93.2% (95% confidence
interval [CI], 83.5 to 98.1%) and 93.6% (95% CI, 90.1 to
96.1%), respectively. The apparent false-positive and false-
negative MultiCode-PLx system results were adjudicated by a
single-target PCR assay for INF A. INF A RNA was detected
in 89.5% of the samples with apparent false-positive results
and 75% of the samples with apparent false-negative results by
the single-target PCR assay for INF A.
A two-by-two contingency table for the detection of RSV by
the different test methods was prepared, and the results are as
follows: among the samples with positive MultiCode-PLx sys-
tem results, 11 were DFA and R-mix culture positive and 2
were DFA and R-mix culture negative (both samples tested
positive for RSV by a single-target PCR assay). Among the
samples with negative MultiCode-PLx system results, 1 was
DFA and R-mix culture positive (the sample tested negative
for RSV by a single-target PCR assay) and 340 were DFA and
R-mix culture negative. The agreement between the methods
was 99.2%. The sensitivity and specificity of MultiCode-PLx
system relative to the results of DFA staining plus R-mix cul-
ture for the detection of RSV were 91.7% (95% CI, 61.5 to
99.8%) and 99.4% (97.7 to 99.8%), respectively (P 	 1.0,
McNemar’s test). Of the 12 samples positive by DFA and
R-mix culture, 3 were detected by DFA only. RSV RNA was
found by single-target PCR assays for RSVs A and B in the
two specimens with apparent false-positive results with the
MultiCode-PLx system and not in the single sample with appar-
ent false-negative results with the MultiCode-PLx system.
The MultiCode-PLx system detected 27 viruses that were
not covered by DFA plus R-mix culture, including 9 HMPVs,
16 HRVs, 1 NL63 strain, and 1 OC43 strain. The agreement
between the MultiCode-PLx system results and the results of
single-target PCR assays for these viruses is shown in Table 3.
All of the positive results for HMPV, NL63, and OC43 ob-
tained with the MultiCode-PLx system and 81.3% of the re-
sults for HRV obtained with the MultiCode-PLx system were
confirmed by the single-target PCR assays. Overall, the single-
target PCRs verified the MultiCode-PLx system results for 73
of 81 (90.1%) of specimens whose results were discordant with
those of DFA and R-mix culture or that were not covered by
DFA and R-mix culture.
Two mixed infections were detected by the MultiCode-PLx
system and none were detected by DFA plus R-mix culture.
For one sample the MultiCode-PLx system was positive for
HMPV and HRV, and for the second sample the MultiCode-
PLx system was positive for OC43 and HRV.
Seventy-three specimens were tested by both operators by
use of the MultiCode-PLx system; 44 were positive and 29 were
negative for viral targets. The same result was obtained by each
operator with 68 (93.1%) of the specimens. When the results
differed, it was a no call that occurred because one or both of
the IPCs were not detected.
DISCUSSION
Nucleic acid-based diagnostics for respiratory viruses have
emerged as the new “gold standards.” However, the large
number of potential etiologies of respiratory tract infections
demands a massively multiplexed approach. Use of a combi-
nation of reagents to detect multiple pathogens in a single
PCR often results in a loss of sensitivity for each of the indi-
vidual targets. In addition, there are limitations in the number
of targets that can be detected in a multiplex assay. Real-time
PCR assays with fluorescent reporters require the use of non-
overlapping spectra for each reporter dye, which limits the
number of targets to five or less with most instruments. An
end-point PCR with a gel-based readout requires amplicons
that can be clearly distinguished by size. While it is possible to
detect more targets by this approach, the amplification of tar-
gets of different sizes often results in different target amplifi-
cation efficiencies.
The MultiCode-PLx system overcomes both limitations of
standard multiplex analysis. The high mean fluorescence in-
tensities for positive samples and the agreement between the
results obtained with the MultiCode-PLx system and those
obtained by single-target PCR suggest that it is possible to
perform a massively multiplex analysis with little loss of sensi-
tivity. The individually addressable, color-coded polystyrene
beads used to capture specific target amplicons allowed the
effective discrimination of 19 discrete analytes per sample in
this respiratory virus panel.
We tested patient specimens for respiratory viruses using a
prototype MultiCode-PLx system capable of detecting 17 dif-
ferent respiratory viruses. All samples were tested in parallel
with R-mix rapid culture. R-mix culture was chosen as the
comparator because the sensitivity is comparable to that of
conventional cell culture but provides results in 24 to 48 h (11).
The diagnostic yields with the R-mix culture and MultiCode-
PLx systems were similar for the viruses detected by both
assays except INF A. The MultiCode-PLx system detected
significantly more INF A-positive samples. The 25.4% increase
in sensitivity over the results of R-mix culture is consistent with
other reports of increased yields with PCR assays for INF A
(14).
The MultiCode-PLx system provides additional diagnostic
capabilities beyond those available with the R-mix culture sys-
tem. HMPV is responsible for a substantial portion of lower
respiratory tract infections in infants and young children and is
second only to RSV as a cause of bronchiolitis in early child-
hood (21). In adults HMPV has been associated with influenza-
like illness, bronchitis, pneumonia, and exacerbations of both
asthma and chronic obstructive pulmonary disease. It can also
cause prolonged and serious infections in the immunocompro-
mised host. We detected HMPV in 2.5% of the samples tested
with the MultiCode-PLx system. Falsey et al. (15) detected
HMPV with a single-target RT-PCR in 3.4% of adults with
respiratory tract illness.
The PLx RVP included three HCoV strains: OC43, 229E,
TABLE 3. Agreement between MultiCode-PLx system and single-
target PCR results for viruses not covered by DFA
staining and R-mix culture
Virus No. of MultiCode-PLXsystem-positive specimens
No. (%) of single-target
PCR positive specimens
HRV 16 13 (81)
HMPV 9 9 (100)
NL63 2 2 (100)
OC43 1 1 (100)
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and recently discovered strain NL63 (31). HCoVs cause a wide
variety of respiratory illnesses in children and adults; however,
the clinical impact of the illnesses has not yet been fully de-
termined. We found two patients infected with NL63 (0.6%),
one patient (0.3%) infected with OC43, and no patient in-
fected with 229E. Most of the data on the prevalence of NL63
is for children, for whom the rates of detection range from 2.1
to 9.3% of patients with acute respiratory illness (19). Strains
OC43 and 229E demonstrate periodicity, with large epidemics
occurring every 2 to 3 years (22). Since 2003, five HCoVs have
been discovered, including the sudden acute respiratory syn-
drome, NL63, NL, NH, and HKU1 viruses (22). Several of
these recently discovered HCoVs are candidates for inclusion
in a comprehensive RVP.
HRVs are the most common causes of upper respiratory
tract illnesses and asthma exacerbations in ambulatory chil-
dren and adults (19). In addition, HRVs have been linked to
prolonged cough illness in children, lower respiratory tract
disease in stem cell transplant recipients, rejection in lung
transplant recipients, and serious infections in elderly individ-
uals. We detected HRVs in only 4.5% of the samples that we
tested with the MultiCode-PLx system. This relatively low pos-
itive rate probably reflects the fact that the majority of samples
came from hospitalized patients with potentially more serious
respiratory illnesses.
The MultiCode-PLx system also distinguishes between anti-
genic subgroups A and B of PIV 4; subgenera B, C, and E of
respiratory ADVs; and antigenic subgroups A and B of RSV.
This capability is of more value in epidemiological studies and
surveillance activities than for the management of individual
patients. The MultiCode-PLx system should provide a better
means to detect infections of mixed viral etiology. However, in
this study only 1.7% of the infections detected by the Multi-
Code-PLx system involved more than one virus.
The diagnostic capacity of the MultiCode-PLx system could
easily be extended beyond the 17 viruses included in the panel
that we tested. In theory, up to 80 different targets could be
detected in a MultiCode-PLx system, since 80 distinct tags are
available. Other candidates for a respiratory virus panel in-
clude enteroviruses, human bocavirus, hantaviruses, and avian
influenza viruses, in addition to the newly recognized HCoVs
discussed above. This list will expand as new respiratory viruses
emerge and their clinical importance is established.
The MultiCode-PLx system is robust, and when it is coupled
with the MagNA Pure total nucleic acid extraction kit, it is
capable of providing results for a wide variety of respiratory
sample types. It is a one-tube, three-step, 4-h process that does
not involve extensive sample washes or transfers and that uses
equipment that is already available in many clinical laborato-
ries. The labeling of the amplicons and room temperature
decoding of tagged target extenders are accomplished through
the use of a nonnatural base pair, iC and iG. The PCR step is
highly multiplexed, which may be the reason why stringent
cycling conditions were required. We found that the PTC-200
cyclers performed well, but the use of less precise cyclers could
be problematic.
Use of the MultiCode-PLx system is technically demanding,
but no more so than the use of other PCR-based assays. Al-
though there are no sample transfers, the MultiCode-PLx sys-
tem plates must be unsealed and resealed three times during
the procedure to add reagents. The unsealing of the plates
could potentially cause false-positive results due to sample or
amplicon carryover if the unsealing is not done carefully. How-
ever, single-target PCRs verified the positive MultiCode-PLx
system results for 90.1% of the specimens that had results
discordant with those of DFA and R-mix culture or that had
viruses not covered by DFA and R-mix culture. In addition,
none of the negative controls included with each MultiCode-
PLx system run tested positive for any of the targets included
in the panel. These results alleviated our initial concerns about
carryover contamination, but as is the case with any PCR
protocol, proper sample handling and laboratory work flow
should be maintained.
In the version that we tested, the MultiCode-PLx system
incorporated both DNA and RNA IPCs in each sample. The
DNA IPC provides a check that the amplification, TSE, and
detection reactions and the instrument are functioning appro-
priately. The RNA IPC checks the function of all steps of the
procedure, including sample preparation and RT. We believe
that higher RNA IPC failure rates may indicate that our sam-
ple preparation method needs further optimization for the
recovery of RNA targets from respiratory tract samples.
The optimal use of external positive controls for massively
multiplexed molecular diagnostics is yet to be defined. In this
trial with an alpha version of the system, we included external
positive controls for each of the 17 different analytes with each
run. To minimize the number of wells devoted to external
positive controls, three positive controls were included in one
well, and two positive controls were combined in each of seven
other wells. This strategy would be impractical for routine
use. Laboratories adopting this technology could chose to
run the full battery of external positive controls with each
new lot of reagents and rotate a different subset of the
controls with each run.
This is the first trial of the MultiCode-PLx system in a
clinical laboratory setting and was conducted by technologists
with experience in molecular diagnostic techniques. Our expe-
rience demonstrates that this massively multiplexed approach
to respiratory viral diagnostics is feasible in this setting. The
MultiCode-PLx system uses multichannel pipettors, a standard
thermal cycler, and a microsphere flow cytometer, which are
available in many clinical laboratories. In our experience, ap-
proximately 32 samples could be processed and analyzed in an
8-h shift. Although timing studies were not performed, we
estimate that each sample requires about 4 min of hands-on
time. As many as 80 samples per shift can be analyzed when the
assay starts with purified nucleic acid.
The relatively small numbers of specimens with viruses other
than INF A and RSV and the use of single-target PCR tests in
subset analyses are the major limitations of this study. Since
the prevalence of the individual respiratory viruses varies from
year to year and by geography, multicenter clinical trials sup-
plemented by assays with banked samples will be necessary to
accurately assess the performance characteristics of the Multi-
Code-PLx system. Given the limitations of antigen detection
and culture, we chose single-target PCR assays to adjudicate
the results obtained with the MultiCode-PLx system. The re-
sults may differ if other single-target PCR assays are used as
comparators, because standardized assays for many of the tar-
gets included in the respiratory virus panel are not available.
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Lee et al. (24) recently described the development and ver-
ification of a multiplex PCR-microsphere flow cytometry sys-
tem similar to the one described here for the comprehensive
detection of respiratory viruses in nasal lavage samples from
children with asthma. They found similar rates of detection
with this system and conventional virological methods for INF
A, INF B, and PIV 1. The new system had improved rates of
detection for RSV, PIV 3, PIV 4, HRV, and enteroviruses,
with the increases in the diagnostic yields over those of con-
ventional methods ranging from 23.8% to 72.8%.
Two other multiplex respiratory pathogen assays that use
microsphere liquid arrays are in commercial development
(Genaco [QIAGEN, Hilden Germany] and Tm Bioscience
[Luminex]). The systems differ in their compositions of the
respiratory virus panels, the methods by which the PCR prod-
ucts are labeled, and the numbers of analysis steps. Brunstein
and Thomas (7) reported a complete concordance between the
results of DFA staining and those of the Genaco assay for the
detection of respiratory viruses in 18 clinical samples. To our
knowledge no information on the performance characteristics
of the Tm Bioscience assay has been published.
MassTag PCR is another novel approach to the highly mul-
tiplexed detection of respiratory pathogens that compares
favorably with other methods (6). It uses a multiplex PCR in
which the viral gene targets are coded by a library of up to 64
distinct Masscode tags (QIAGEN, Hilden, Germany). The tar-
gets are amplified with primers labeled by a photocleavable
link to molecular tags of different molecular weights. After
removal of unincorporated primers, the tags are released by
UV irradiation and analyzed by mass spectroscopy. The iden-
tity of the virus in the clinical sample is determined by the
presence of its cognate tag. In a recent study, the MassTag
system was compared with single-target RT-PCR and conven-
tional virus culture for the detection of 22 different respiratory
pathogens in 151 clinical samples (23). The diagnostic yield
with the MassTag system was much greater, detecting patho-
gens in 33% of the samples that were negative by the other
methods.
The increased laboratory costs of a rapid and comprehensive
respiratory virus diagnostic assay could be offset through the
improvement of patient management by influencing the deci-
sion to initiate antibiotic or antiviral therapy and implementing
infection control measures to prevent transmission, particu-
larly in hospitalized patients (3, 26, 33). However, a recent
study of the impact of the rapid detection of viral and atypical
bacterial pathogens by a large number of single-target, real-
time PCR runs in parallel for patients with lower respiratory
tract infections did not reduce antibiotic use or health care
costs (16). A detailed cost analysis was beyond the scope of this
study, but preliminary estimates indicate that the MultiCode-
PLx system will be more costly than the combination of antigen
detection and culture methods that are currently the standard
of practice in many laboratories but less costly than 17 single-
target PCR assays run in parallel or the use of culture-based
systems that provide equally broad coverage for respiratory
viruses.
In summary, the MultiCode-PLx system provides a rapid,
sensitive, and comprehensive approach to the molecular de-
tection of respiratory viruses that has several advantages over
other multiplexing protocols. It is a practical and robust
method that is feasible for use by clinical laboratories with the
potential to dramatically increase diagnostic yields.
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